Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Venezuela keen on J&J vaccine but seeks details on side effects, official says

04/26/2021 | 04:32pm EDT

CARACAS, April 26 (Reuters) - Venezuela is interested in acquiring the Johnson & Johnson coronavirus vaccine for its inoculation campaign, parliament chief Jorge Rodriguez said on Monday, adding that authorities want to know more about its side effects.

The COVAX global vaccine program has set aside doses of the AstraZeneca shot for Venezuela, but the government of President Nicolas Maduro blocked its use after reports of rare but serious blood clots led some European nations to temporarily stop delivering it.

Though similar rare side effects have also emerged in association with the J&J shot, it offers a lower cost and easier logistics than other vaccines because it is administered in a single dose, he said.

"There was a certain amount of noise with respect to the Johnson & Johnson vaccine, that is the vaccine we are looking for at the moment," Rodriguez said during an interview in the legislative palace. "We have to wait to see what the studies say."

The U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration last week recommended resuming use of the J&J shot after a 10-day pause to investigate its link to extremely rare but potentially deadly blood clots.

Venezuela's government for months held talks with advisers to opposition leader Juan Guaido about paying for COVAX using funds frozen in the United States as part of Washington's sanctions against Maduro's government.

Officials this month said they had made two payments for the complete amount owed. Rodriguez said as a result, Venezuela has now decided on the COVAX option that allows countries to choose which vaccine they want, even though this will cost more.

"At the same time, President Maduro is looking in other markets, in secondary markets, ... with the governments of the countries and also with private intermediaries for the acquisition of vaccines," Rodriguez said.

Venezuela is also interested in the vaccine manufactured by China's Sinopharm, Rodriguez said.

The World Health Organization by the end of the week will review the Sinopharm vaccine for possible emergency use listing.

China in February said it plans to provide 10 million doses of COVID-19 vaccines to COVAX, including from Sinopharm.

Venezuela so far has received 880,000 vaccine doses, 380,000 of Russia's Sputnik V shot and another 500,000 of China's Sinopharm.

The South American nation has reported relatively low numbers of coronavirus cases and deaths.

Venezuelan academies of medicine and science this year said this was the result of early lockdown measures as well as gasoline shortages in 2020 that limited citizen mobility along with spread of the disease.

(Reporting by Brian Ellsworth and Deisy Buitrago; Editing by Bill Berkrot)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.37% 8352 Delayed Quote.14.47%
SINOPHARM GROUP CO., LTD. -4.25% 22.55 End-of-day quote.19.57%
All news about ASTRAZENECA PLC
06/18ASTRAZENECA  : Argentine lab makes first half million doses of Russian COVID-19 ..
06/18Ontarians cancelling AZ doses after new guidance, province still offering dos..
06/18Health Care Down Amid Defensive Bias -- Health Care Roundup
06/18Eurostoxx 50 : European shares deepen losses after hawkish Fed comments
06/18THE LATEST : Brazil to hit 500K deaths, 2nd highest globally
06/18ASTRAZENECA  : Ordered by Brussels Court to Deliver 80.2 Million COVID-19 Jabs t..
06/18ASTRAZENECA  : claims victory over EU in vaccine deliveries case
06/18ASTRAZENECA  : EU both claim a win in vaccine delivery tussle
06/18ASTRAZENECA  : Welcomes Belgian Court Ruling on COVID-19 Vaccine Supply to EU
More news
Financials (USD)
Sales 2021 30 966 M - -
Net income 2021 4 588 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,5x
Yield 2021 2,47%
Capitalization 152 B 152 B -
EV / Sales 2021 5,25x
EV / Sales 2022 4,49x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 133,03 $
Last Close Price 115,73 $
Spread / Highest target 47,7%
Spread / Average Target 14,9%
Spread / Lowest Target -16,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.47%151 865
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795